Lipids, Lipoproteins, and Atherothrombotic Disease: Clinical Pharmacology Now and in the Future

Dear Colleagues,

Despite the success of statin therapy for decreasing the plasma levels of LDL cholesterol, cardiovascular disease and stroke remain major causes of death in developed countries. Even in subjects at high cardiovascular risk that achieve the target triglyceride and cholesterol levels proposed by international societies, cardiovascular and ischemic events still occur. Although novel and highly effective lipid-lowering therapies such as PCSK9 inhibitors have been developed in recent years, there is an urgent need to develop novel therapies to improve the clinical management of the atherothrombotic disease. Recent studies point to alternative therapeutic targets that could not be only addressed to quantitatively decrease lipid levels in blood but also to improve the function and qualitative characteristics of lipoproteins, thereby decreasing the cardiovascular risk.

This Special Issue on “Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future” aims to update the current pharmacological strategies and to present possible new therapeutic targets that have emerged in recent years. We welcome the submission of original research and review articles on novel molecular mechanisms implicated in the development of cardiovascular and atherothrombotic disease, as well as recent advances in drug targets and therapeutic approaches.

Dr. Jose Luis Sanchez-Quesada
Dr. Sonia Benítez González
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.